LUDGER LIMITED

Their core work

Ludger is a UK-based SME specializing in glycan analysis — the science of characterizing sugar structures (glycans) attached to proteins and other biological molecules. They provide analytical tools, reagents, and expertise for glycosylation profiling, which is critical for biopharmaceutical quality control, disease biomarker discovery, and nanomedicine development. In H2020 projects, they contribute their glycan characterization capabilities to training networks focused on cancer diagnostics, precision medicine, biologics analytics, and glyco-nanoparticle applications.

What they specialise in

How they've shifted over time

Ludger's earlier H2020 projects (2015-2017) focused on applying glycan analysis to established biomedical challenges — cancer diagnostics (GlyCoCan) and precision medicine (GlySign), plus biologics quality control (A4B). Their most recent project, NanoCarb (2018), moved into glyco-nanoparticle interactions, bionano corona characterization, and carbohydrate-based nanomedicine — a clear expansion from pure analytical services toward the nano-bio interface. This progression shows a company moving from established glycobiology applications toward more frontier territory where glycan science meets nanotechnology.

Ludger is expanding from traditional glycan analysis for biopharma toward nano-bio interface characterization, positioning them for emerging nanomedicine and advanced therapy applications.

How they like to work

Ludger participates exclusively as a partner — never as coordinator — across all four projects, consistent with a specialist SME contributing defined analytical capabilities to larger research training networks. With 43 unique consortium partners across 15 countries, they work in broad, internationally diverse consortia typical of MSCA training networks (10-15 partners each). This pattern suggests they are a reliable, sought-after niche contributor rather than a project driver.

Ludger has collaborated with 43 distinct partners across 15 countries through MSCA training networks, giving them a wide European research network in glycoscience and biopharma analytics. Their connections likely span universities, research institutes, and industry partners across Western and Central Europe.

What sets them apart

Ludger occupies a rare niche as a commercial glycan analysis SME embedded in academic training networks — most glycan expertise sits in university labs, not private companies with commercial products and services. Their consistent selection for MSCA training networks (4 out of 4 projects) signals that they are valued for providing early-career researchers with industry-grade analytical training. For consortium builders, Ludger brings both technical glycan characterization and a strong industry training component that MSCA evaluators look for.

Highlights from their portfolio

• GlySign
  Largest funding (EUR 546,576) and focused on exploiting glycosylation signatures for precision medicine — the most commercially translatable of their projects.
• NanoCarb
  Most recent project (2018-2023) representing Ludger's expansion into glyco-nanoparticle characterization and nanomedicine, signaling a new strategic direction.
• A4B
  Directly addresses biologics quality analytics — the area closest to Ludger's core commercial business of glycan analysis tools and services.